Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview

被引:0
作者
Dionysis D. Balatsoukas
Konstantinos T. Tsaousis
Konstadinos G. Boboridis
Anastasios G. Konstas
Fotis Topouzis
机构
[1] Aristotle University of Thessaloniki,1st University Department of Ophthalmology
[2] General Hospital of Volos,1st and 3rd University, Departments of Ophthalmology
[3] Aristotle University of Thessaloniki,undefined
来源
Advances in Therapy | 2022年 / 39卷
关键词
Anti-vascular endothelial growth factors (VEGF); nAMD therapy; Neovascular age-related macular degeneration;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:5 / 32
页数:27
相关论文
共 99 条
  • [1] Wong WL(2014)Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis Lancet Glob Health 2 e106-e116
  • [2] Su X(2017)Early and intermediate age-related macular degeneration: update and clinical review Clin Interv Aging 12 1579-1587
  • [3] Li X(2012)Mechanisms of age-related macular degeneration Neuron 75 26-39
  • [4] García-Layana A(2017)Prevalence of age-related macular degeneration in europe: the past and the future Ophthalmology 124 1753-1763
  • [5] Cabrera-López F(2010)Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy Pharmaceuticals 3 572-599
  • [6] García-Arumí J(2000)VEGF is major stimulator in model of choroidal neovascularization Investig Ophthalmol Vis Sci 41 3158-3164
  • [7] Arias-Barquet L(2013)Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration Br J Ophthalmol 97 1443-1446
  • [8] Ruiz-Moreno JM(2018)The burden of neovascular age-related macular degeneration: a patient’s perspective Clin Ophthalmol 12 2483-2491
  • [9] Ambati J(2019)Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration Clin Ophthalmol 13 1323-1329
  • [10] Fowler BJ(2014)Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study Am J Ophthalmol 158 724-732.e2